Salt Lake City--SAB CAPRA, LLC, a privately-held, emerging bioscience company developing targeted human polyclonal antibodies for use in diagnostics, testing and immunotherapeutics, was awarded a $225,000 grant from the National Institutes of Health to advance Its novel immunotherapy platform in collaboration with UTAH STATE UNIVERSITY and will target pandemic Influenza.

PositionAround Utah

Salt Lake City -- SAB CAPRA, LLC, a privately-held, emerging bioscience company developing targeted human polyclonal antibodies for use in diagnostics, testing and immunotherapeutics, was awarded a $225,000 grant from the National Institutes of Health to advance Its novel immunotherapy platform in collaboration with UTAH STATE UNIVERSITY and will target pandemic Influenza. The company will use the funds...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT